Proceedings

Abstract Book

Jump to: Conference Research

133 pages, 926 KiB

Open AccessMeeting Report

Abstracts of the 25th Biennial International Congress on Thrombosis

by Vittorio Pengo and Paolo Prandoni

Proceedings 2018, 2(9), 531; https://doi.org/10.3390/proceedings2090531 - 12 Oct 2018

Cited by 1 | Viewed by 3478

Abstract

This Issue collates the abstracts presented at the 25th Biennial International Congress on Thrombosis held on 23–26 May 2018. Prevention and treatment of thromboembolic events is a main issue in medicine that involves all the components of the health care system. Recently, a [...] Read more.

This Issue collates the abstracts presented at the 25th Biennial International Congress on Thrombosis held on 23–26 May 2018. Prevention and treatment of thromboembolic events is a main issue in medicine that involves all the components of the health care system. Recently, a strong boost in this field came from the introduction of new antithrombotic agents whose use is expanding with the need for more information obtained by real-life studies. Thus, ICT 2018 was an important venue to compare clinical experiences and learn new advances in basic and pharmacological sciences. Full article

(This article belongs to the Proceedings of The 25th Biennial International Congress on Thrombosis)

Conference Research

Jump to: Abstract Book

4 pages, 347 KiB

Open AccessProceeding Paper

Genetic Testing for Inherited Thrombophilia: 20 Years of Experience in a University and Tertiary Care Centre

by Cláudia Vaz, Francisco Bischoff, Fátima Monteiro, Manuela Lopes, Filipe Vasconcelos, Pedro Bastos, Gilberto Tavares, Marina Ferreira, Ana Amorim and Carmo Koch

Proceedings 2018, 2(9), 527; https://doi.org/10.3390/proceedings2090527 - 19 Jul 2018

Cited by 1 | Viewed by 2285

Abstract

Inherited thrombophilias are a group of clinical conditions in which there is a genetic variant defect associated with a predisposition to thrombosis. Genetic testing for inherited thrombophilias has been used in the diagnosis of specific thrombophila at our centre for the last 20 [...] Read more.

Inherited thrombophilias are a group of clinical conditions in which there is a genetic variant defect associated with a predisposition to thrombosis. Genetic testing for inherited thrombophilias has been used in the diagnosis of specific thrombophila at our centre for the last 20 years, this work will summarize our experience. Full article

(This article belongs to the Proceedings of The 25th Biennial International Congress on Thrombosis)

► Show Figures

Figure 1

4 pages, 457 KiB

Open AccessProceeding Paper

Initial Results of Oral Thrombolytic Agent Clinical Application

by Pavel Madonov, Stanialav Leont’ev, Sergey Zotov, Maksim Ufimtsev, Svetlana Mishenina and Dmitrii Kinsht

Proceedings 2018, 2(9), 530; https://doi.org/10.3390/proceedings2090530 - 20 Jul 2018

Cited by 1 | Viewed by 2041

Abstract

At the moment, there is no oral thrombolytic drug on the world pharmaceutical market. The drug Trombovazim, which has a thrombolytic effect under oral administration, has been registered in Russia. It differs from all thrombolytics—it has a fundamentally different mechanism of action. It [...] Read more.

At the moment, there is no oral thrombolytic drug on the world pharmaceutical market. The drug Trombovazim, which has a thrombolytic effect under oral administration, has been registered in Russia. It differs from all thrombolytics—it has a fundamentally different mechanism of action. It is not an activator of plasminogen. It independently dissolves a thrombus. It is a direct thrombolytic. The article presents the materials of the initial studies of the drug Trombovazim. Full article

(This article belongs to the Proceedings of The 25th Biennial International Congress on Thrombosis)

► Show Figures

Figure 1

2 pages, 142 KiB

Open AccessProceeding Paper

An Italian Registry on Risk Factors for Venous Thromboembolism in Blood Donors Clinicaltrials. Gov: Nct03282747

by Elvira Grandone, Angelo Ostuni, Lazzaro di Mauro, Nadia Coffetti, Anna Turrini, Giobatta Cavallero, Patrizia Vergura, Filomena Cappucci, Antonio de Laurenzo, Michela Villani, Nicola Di Renzo, Alberto Tosetto and Maurizio Margaglione

Proceedings 2018, 2(9), 532; https://doi.org/10.3390/proceedings2090532 - 25 Jul 2018

Viewed by 1642

Abstract

A registry-based study to evaluate prevalence of common risk factors for vein thrombosis among healthy subjects. Full article

(This article belongs to the Proceedings of The 25th Biennial International Congress on Thrombosis)

3 pages, 193 KiB

Open AccessProceeding Paper

Evaluation of the Plasmic Score for the Prediction of Adamts13 Activity in Patients with Thrombotic Microangiopathies

by Giovanni Tiscia, Filomena Cappucci, Potito Scalzulli, Nicola Cascavilla, Cosima Battista, Antonio Abrescia, Filippo Aucella, Caterina Buquicchio, Maurizio Brigante, Giovanna Dandrea, Bruno Di Paolo, Giulio Giordano, Barbara Infante, Silvia Piano, Prudenza Ranieri, Livio Tullo, Angelo Ostuni and Elvira Grandone

Proceedings 2018, 2(9), 533; https://doi.org/10.3390/proceedings2090533 - 26 Jul 2018

Cited by 1 | Viewed by 2061

Abstract

The PLASMIC score for the prediction of a likelihood of a severe ADAMTS13 deficiency represents a valid pre-test diagnostic tool to identify patients with thrombotic thrombocytopenic purpura. Full article

(This article belongs to the Proceedings of The 25th Biennial International Congress on Thrombosis)

► Show Figures

Figure 1

4 pages, 188 KiB

Open AccessProceeding Paper

Variations in Mean Platelet Volume in Patients with Helicobacter pylori Infection before and after Eradication, Way before Immune Thrombocytopenia?

by Burcu Dag, Elif G. Umit and Hasan Umit

Proceedings 2018, 2(9), 529; https://doi.org/10.3390/proceedings2090529 - 27 Jul 2018

Cited by 1 | Viewed by 1703

Abstract

Helicobacter pylori (H. pylori) and immune thrombocytopenia (ITP) association is well known and eradication treatment has its place in both treatment guidelines. Since H. pylori eradication is followed by an increase in platelet counts in patients with immune thrombocytopenia, it is [...] Read more.

Helicobacter pylori (H. pylori) and immune thrombocytopenia (ITP) association is well known and eradication treatment has its place in both treatment guidelines. Since H. pylori eradication is followed by an increase in platelet counts in patients with immune thrombocytopenia, it is suggested that H. pylori be examined and treated if infection is present. There is only one study that demonstrated a relation between H. pylori and platelet indices in individuals with normal platelet counts. In this study, we aimed to investigate the effects of H. pylori infection on platelet count and mean platelet volume, which is a sign of increased platelet destruction in patients with normal platelet counts. We evaluated the data of 106 patients with urease test positivity before the eradication of bacteria and urea breath test negative after the eradication, in a retrospective manner. Mean platelet count in patients before the eradication treatment was 256.730 ± 66.380/mm³. After H. pylori was eradicated, it has been observed that the mean platelet count increased to 287.080 ± 59.240/mm³. Mean MPV of patients before and after eradication treatment were 9.35 ± 1.63 fL and 8.61 ± 1.48 fL. Mean MPV was higher when patients were infected with H. pylori. This study showed that there is an increase in platelet counts and a decrease in MPV levels with the eradication of the H. pylori. Our study is the first to investigate changes of mean platelet volume and platelet count before and after eradication of H. pylori infection in individuals with normal platelet counts. Full article

(This article belongs to the Proceedings of The 25th Biennial International Congress on Thrombosis)

4 pages, 410 KiB

Open AccessProceeding Paper

Predicting Recurrence after a First Unprovoked Venous Thromboembolism: Retrospective Validation of the DAMOVES Score

by A. I. Franco Moreno, M. J. García Navarro, C. L. De Ancos Aracil, A. Gimeno García, C. Montero Hernández, A. Villa Martínez, V. Piedrafita Mateo, J. Ortiz Sánchez, I. C. Sanz Acevedo, R. Martín Díaz and J. M. Ruiz Giardín

Proceedings 2018, 2(9), 528; https://doi.org/10.3390/proceedings2090528 - 30 Jul 2018

Viewed by 1520

Abstract

Unprovoked venous thromboembolism is associated with a 5 to 27% annual risk of recurrence after discontinuation of anticoagulation, and indefinite anticoagulation is recommended if the bleeding risk is low to moderate. However, in one-third of patients with unprovoked venous thromboembolism, the risk of [...] Read more.

Unprovoked venous thromboembolism is associated with a 5 to 27% annual risk of recurrence after discontinuation of anticoagulation, and indefinite anticoagulation is recommended if the bleeding risk is low to moderate. However, in one-third of patients with unprovoked venous thromboembolism, the risk of recurrence is so low (<5% per year) that anticoagulant therapy >3–6 months may not be necessary. Several prediction rules were derived to identify patients with unprovoked venous thromboembolism who have a low recurrence risk. In 2016, we presented our results of the original DAMOVES, a nomogram for prediction of recurrence in an individual patient with unprovoked venous thromboembolism. The aim of this study was to externally validate this nomogram in patients with unprovoked venous thromboembolism. Full article

(This article belongs to the Proceedings of The 25th Biennial International Congress on Thrombosis)

► Show Figures

Figure 1

Journal Menu

Journal Browser

Proceedings, 2018, ICT 2018

The 25th Biennial International Congress on Thrombosis

Abstract Book

Conference Research

Further Information

Guidelines

MDPI Initiatives

Follow MDPI